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Background. Tobacco companies have actively promoted the sub-
stitution of cigarettes with purportedly safer tobacco products (e.g.,
smokeless tobacco, e-cigarettes) as tobacco harm reduction (THR). Given
the tobacco, e-cigarette, and pharmaceutical industries’ substantial
ﬁnancial interests, we quantiﬁed industry inﬂuence on support for THR.
Objectives. To analyze a comprehensive set of articles published in
peer-reviewed journals assessing funding sources and support for or op-
position to substitution of tobacco or nicotine products as harm reduction.
Search Methods. We searched PubMed, Embase, Web of Science, and
PsycINFO with a comprehensive search string including all articles,
comments, and editorials published between January 1, 1992 and July 26,
2016.
SelectionCriteria. We included English-languagepublications published
in peer-reviewed journals addressing THR in humans and excluded studies
on modiﬁed cigarettes, on South Asian smokeless tobacco variants, on
pregnant women, on animals, not mentioning a tobacco or nicotine
product, on US Food and Drug Administration–approved nicotine re-
placement therapies, and on nicotine vaccines.
Data Collection and Analysis. We double-coded all articles for article
type; primary product type (e.g., snus, e-cigarettes); themes for and
against THR; stance on THR; THR concepts; funding or afﬁliation with
tobacco, e-cigarette, pharmaceutical industry, or multiple industries; and
each author’s country.We ﬁt exact logistic regression models with stance
onTHRas theoutcome (pro- vs anti-THR) and sourceof fundingor industry
afﬁliation as the predictor taking into account sparse data. Additional
models included article type as the outcome (nonempirical or empirical)
and industry funding or afﬁliation as predictor, and stratiﬁed analyses for
empirical and nonempirical studies with stance on THR as outcome and
funding source as predictor.
Main Results. Searches retrieved 826 articles, including nonempirical
articles (21%), letters or commentaries (34%), editorials (5%), cross-
sectional studies (15%), systematic reviews and meta-analyses (3%), and
randomized controlled trials (2%). Overall, 23.9% disclosed support by
industry; 49% of articles endorsed THR, 42% opposed it, and 9% took
neutral or mixed positions. Support from the e-cigarette industry
(odds ratio [OR] = 20.9; 95% conﬁdence interval [CI] = 5.3, 180.7),
tobacco industry (OR=59.4; 95% CI = 10.1, +inﬁnity), or pharmaceutical
industry (OR=2.18; 95% CI = 1.3, 3.7) was signiﬁcantly associated
with supportive stance on THR in analyses accounting for sparse data.
Authors’ Conclusions. Non–industry-funded articles were evenly di-
vided in stance, while industry-funded articles favored THR. Because of
their quantity, letters and comments may inﬂuence perceptions of THR
when empirical studies lack consensus.
Public Health Implications. Public health practitioners and researchers
need to account for industry funding when interpreting the evidence in
THR debates. (Am J Public Health. Published online ahead of print May 16,
2019: e1–e8. doi:10.2105/AJPH.2019.305106)
PLAIN-LANGUAGE SUMMARY
Tobacco harm reduction is one of the most
divisive issues in tobacco control. Tobacco
companies have promoted substitution of po-
tentially safer tobacco products as tobacco harm
reduction. Given the tobacco, e-cigarette, and
pharmaceutical industries’ substantial ﬁnancial
interests in product substitution, in this study, we
quantiﬁed industry inﬂuence supporting tobacco
harm reduction. We systematically reviewed a
comprehensive set of articles published in peer-
reviewed journals to examine the relationship
between industry funding and stance on tobacco
harm reduction. We reviewed 4 major databases
and all articles, comments, letters, and editorials
published between January 1992 and July 2016.
Of the 826 articles ﬁtting the study criteria, most
were nonempirical articles, letters or com-
mentaries, or editorials. Overall, 23.9% of
articles disclosed support by industry; 49% of
articles endorsed tobacco harm reduction, 42%
opposed it, and 9% took neutral or mixed
positions. Financing from the e-cigarette in-
dustry (odds ratio [OR]=20.9; 95% conﬁ-
dence interval [CI]= 5.3, 180.7), tobacco
industry (OR=59.4; 95% CI=10.1,
+inﬁnity), or pharmaceutical industry
(OR=2.18; 95% CI= 1.3, 3.7) was signiﬁ-
cantly associated with support for tobacco
harm reduction. While non–industry-funded
articles were evenly divided, industry-funded
articles strongly favored tobacco harm re-
duction. Industry-funded literature, especially
letters and comments, may inﬂuence tobacco
harm reduction scientiﬁc dialogue when em-
pirical studies do not provide consensus.
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FIGURE 1—Stance on Tobacco Harm
Reduction (THR) by Funding Source
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In 2001, the Institute of Medicine condi-tionally endorsed reduced-harm tobacco
products as potentially reducing individual
exposure to tobacco toxicants and improving
population-level public health outcomes.1
Since then, tobacco harm reduction (THR)
has been increasingly interpreted as the
complete or partial substitution of cigarettes
with purportedly reduced-harm tobacco
products (e.g., smokeless tobacco, potentially
reduced exposure products, or e-cigarettes).1–3
However, this strategy is supported by few
empirical studies: the American College of
Physicians, the US Preventive Services Task
Force, and theNational Academyof Sciences,
Engineering, andMedicine all concluded that
there is insufﬁcient evidence from random-
ized controlled trials to support the use
of e-cigarettes for smoking cessation.4–6
Nonetheless, THR proponents argue that
alternative tobacco products should be pro-
moted for cessation or long-term nicotine
maintenance if users prefer such products to
established cessation aids such as nicotine
replacement therapies.3,7,8 Other public
health experts argue that alternative tobacco
products should not be endorsed because of a
lack of evidence demonstrating these products’
long-term safety and cessation efﬁcacy.9–11
Articles on THR have proliferated since
2001: a search using the keywords “tobacco”
and “harm reduction” on PubMed yielded 3
articles in 1999, increasing to 112 in 2016
alone. Published studies, reviews, and opin-
ions exhibit strong differences in their stance
on the safety and effectiveness of THR
products, and there may be an association
between stance and funding or ﬁnancial
conﬂicts of interest. The tobacco industry has
actively promoted new tobacco products
including e-cigarettes, embracing the concept
and terminology of THR.12–15 Given the
tobacco, e-cigarette, and pharmaceutical
industries’ substantial ﬁnancial interest in
THR, in this study, we quantiﬁed industry
inﬂuence on stance in published articles
regarding THR.
This article presents an analysis of con-
clusions and stance across a comprehensive set
of articles on THR including articles of all
formats, funding disclosures, and arguments
for and against THR published in peer-
reviewed journals between 1992 and 2016.
Similar to a previous systematic review,16 this
review weighed neither the quality of a
particular study type nor evidence for a single
clinical outcome. Rather, this review de-
liberately included all article types (such as
nonempirical articles, letters, and comments)
so as to systematically evaluate the role of
disclosed funding in inﬂuencing the academic
discourse on THR.Whereas previous studies
have reviewed existing literature on the harm
of e-cigarettes,17 smokeless tobacco,18,19 and
snus,20 each review acknowledged a paucity
of reliable randomized controlled trials in the
literature.9 This systematic review included a
comprehensive broad review of all published
articles from peer-reviewed journals on THR
and examined whether funding, industry
afﬁliation, or other declared support from the
tobacco, e-cigarette, or pharmaceutical in-
dustry was associated with support or oppo-
sition to THR.
METHODS
We conducted a comprehensive review of
all articles, letters, and comments on the topic
of THR published in peer-reviewed journals
between 1992 and 2016. The study was
registered with PROSPERO, protocol
CRD42019115435. In addition, the search
strings and complete codebook are provided
as supplements to the online version of this
article at http://www.ajph.org.
Data Sources and Searches
With the help of a knowledge synthesis
librarian, we searched PubMed, Embase,
Web of Science, and PsycINFO for all articles
relevant to THR and associated topics pub-
lished between January 1, 1992, and July 26,
2016, by using a comprehensive search string
(Appendix A, available as a supplement to
the online version of this article at http://
www.ajph.org). Assessing term frequencies
on PubMed, investigators identiﬁed 1992 as
the ﬁrst year that the term and concept of
“tobacco harm reduction” became popular.
This rise in popularity coincided with the
introduction of potentially reduced exposure
products, followed by cigarette branded
Swedish snus products in the United States
and other smokeless tobacco products. We
iteratively reﬁned the search string to ensure
it was able to capture a test set of 17 THR
articles of different publication types.21,22
Study Selection
We imported all records obtained through
database searches into Covidence,23 a Web-
based software platform. We eliminated
duplicate citations, and 2 of the authors
independently screened 4816 abstracts. We
included abstracts agreed on by both re-
viewers as meeting predetermined criteria
for full text review.
We included English-language publica-
tions addressing the concept of THR in
humans (deﬁned as substituting putatively
safer tobacco products) in the full-text review.
We excluded studies on modiﬁed cigarettes
(e.g., Marlboro UltraSmooth, hookah or
waterpipe, and South Asian smokeless to-
bacco variants like chuna, gutka, and betel
quid), because these products were generally
not considered to be reduced-harm products
in the literature.24–26 We excluded studies
discussing alternative product use in pregnant
women because any form of nicotine con-
sumption (including nicotine replacement
therapies) is generally considered harmful for
this population.27 We also excluded the
following study types: animal studies; theo-
retical studies that exclusively discussed
concepts in THR debates (e.g., “inveterate
smokers”) but did not mention a tobacco or
nicotine product; studies addressing long-
term use of US Food and Drug Adminis-
tration–approved nicotine replacement
therapies; nicotine vaccines; books, theses,
reports, and other literature not published in
peer-reviewed journals; and abstracts from
conference proceedings publications without
a corresponding published article.
ABOUT THE AUTHORS
At the time of the study, all of the authors were affiliated with the Center for Tobacco Control Research and Education and
Department of Medicine at the University of California San Francisco.
Correspondence should be sent to Pamela M. Ling, MD, MPH, 530 Parnassus Ave, Suite 366, University of California San
Francisco, San Francisco, CA 94143-1390 (e-mail: pamela.ling@ucsf.edu). Reprints can be ordered at http://www.ajph.org by
clicking the “Reprints” link.
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We excluded studies only when both
independent reviewers agreed on exclusion.
Disagreements regarding inclusion or exclu-
sion were discussed, with a third reviewer
adjudicating if necessary.
Data Extraction
We extracted data on author names, article
titles, date of publication, ﬁrst author’s
country, and journal name for all articles
included in full-text review. We double-
coded all articles for the following: type of
article, primary product type (e.g., snus, e-
cigarettes), presence of themes for and against
THR, the article’s overall stance on THR
(5-point Likert scale: strongly pro-, weakly
pro-, mixed or neutral, weakly anti-, strongly
anti-), and concept of THR present in the
article (e.g., long-term product substitution).
During this phase of coding, a content-blinded
research assistant, who reviewed disclosed
author afﬁliations and conﬂict of interest
statements, determined funding information
(tobacco, e-cigarette, pharmaceutical industry,
or multiple industries) and other afﬁliation with
industry (such as having authors employed by a
tobacco company), and each author’s country.
Two investigators subsequently validated this
assessment by independently extracting and
verifying industry funding and afﬁliation coding
for the entire data set.
Coding Guideline Development
and Deﬁnitions
We developed a detailed set of coding
guidelines (Appendix B, available as a sup-
plement to the online version of this article at
http://www.ajph.org) to deﬁne the different
arguments used to support and oppose THR
(to aid in consistent assessments of stance on
THR) and to classify different publication
types.
We developed the coding guidelines it-
eratively by reading representative THR
articles to generate a list of themost frequently
used arguments to promote and criticize to-
bacco product substitution as harm reduction.
We coded a sample of 30 articles using the list
to determine reliability, consistency, and the
need for new codes. We revised and retested
the codebook with an additional 30 sample
articles. Through this iterative analysis, we
identiﬁed and deﬁned 29 “pro-THR”
(supporting) and “anti-THR” (criticizing)
arguments. All investigators coded test sets of
articles to clarify the deﬁnitions and revise the
codebook and criteria. Investigators assigned
each article a score based on the number of
pro-THR and anti-THR arguments and the
strength of position each article endorsed.
The 5-point score was simpliﬁed into 3
categories for analysis (i.e., pro-, anti-, neu-
tral). The iterative process of coding test sets
continued until the third set of 40 articles
where argument saturation and greater-than-
70% coding consistency was achieved as
measured by Krippendorff’s a. Two in-
vestigators double-coded all articles in the
data set and differences in coding were
resolved through review and consensus,
with adjudication by a third investigator
as needed.
Similarly, we developed deﬁnitions for
coding publication type, using both pre-
established deﬁnitions of empirical studies
such as cohort studies and cross-sectional
studies and working deﬁnitions of non-
empirical published articles to differentiate
between commentaries, nonsystematic liter-
ature reviews, and editorials, and other
nonempirical opinion pieces. The complete
list of pro-THR and anti-THR arguments
and publication types with examples for each
deﬁnition can be found in the codebook
(Appendix B). An external reviewer validated
the ﬁnal codebook by using the coding
guidelines to independently code a stratiﬁed
random sample of 10 articles from the data set
for comparison.
Data Synthesis and Analysis
We conducted a descriptive analysis of
extracted data to determine the frequency
with which products were discussed, the
number of THR articles by the ﬁrst author’s
country, difference in THR stance by
country, and year of publication (relevant to
when e-cigarettes entered the market). We
also described stance on THR for each
publication type.
To determine association between in-
dustry funding or afﬁliation and stance on
THR, we examined only articles classiﬁed as
pro-THR or anti-THR, excluding neutral
articles. First, we used exact logistic regression
models with stance on THR as the outcome
(pro- vs anti-THR) and source of funding or
industry afﬁliation, which was a categorical
variable and indicated whether articles were
funded by e-cigarette industry, pharmaceu-
tical industry, and tobacco industry as the
predictor. Second, we ﬁt a model with article
type as the outcome (nonempirical or em-
pirical). Because of limited numbers of some
types of articles (e.g., randomized controlled
trials, quasi-experimental studies), we
grouped articles classiﬁed as letters, com-
mentaries, nonempirical articles, and edito-
rials as nonempirical articles. Other article
types were grouped as empirical articles.
Lastly, we conducted a stratiﬁed analysis by
article type with separate models for empirical
and nonempirical studies with stance on
THR as the outcome and funding source as
predictor. We also conducted a sensitivity
analysis including the neutral articles, using
pro-THR versus neutral or anti-THR as
the outcome. We carried out analyses with
Stata version 14 (StataCorp LP, College
Station, TX) and SAS version 9.4 (SAS
Institute, Cary, NC)
RESULTS
In total, we reviewed 4816 unique ab-
stracts and 1041 full-text articles to address
3 key questions. After full-text review, we
excluded 215 articles because they did not ﬁt
review criteria, resulting in 826 articles for
analysis (Figure 2). The list of included articles
can be found in Appendix C (available as a
supplement to the online version of this article
at http://www.ajph.org).
Key Question 1
What types of journal articles on THR
were published in peer-reviewed journals?
Most THRarticles were published after 2004,
with 25% of the sample published between
2004 and 2010 and 66% published after
2010. Overall, 49.2% of total articles were
pro-THR, 9.3% were mixed or neutral, and
41.5% were anti-THR. E-cigarettes were
the most popular product type discussed
(appearing in 48.9% of articles), followed by
smokeless tobacco (19.5%), snus (17.2%),
potentially reduced exposure products (11%),
and other products (3.4%). Based on the af-
ﬁliation of the ﬁrst author, 48.6% of articles in
the data set were from the United States,
followed by the United Kingdom (18.3%),
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Australia (6%), Sweden (5%), and Canada
(5%). Among THR articles from the United
States, 35% were pro-THR and 54.4% were
anti-THR. France and other countries also
had a plurality of anti-THR articles. In the
United Kingdom, however, this distribu-
tion was reversed: 64.9% of articles were
pro-THR versus 26.5% anti-THR. The
majority of English-language articles from
Sweden, Australia, Canada, Italy, New
Zealand, and Switzerland were also
pro-THR (Table 1).
Only 39.4% (326/826) of the included
articles were empirical research articles, while
61% (500/826) were nonempirical letters or
commentaries (34% of the entire sample),
nonempirical articles (21%), and editorials
(5%). The most common types of empirical
studies identiﬁed were cross-sectional studies
(15% of the entire sample), followed by
quasi-experimental studies (6%). Random-
ized controlled trials made up 2% of the
sample.
Randomized controlled trials, non-
empirical studies, and letters or commentaries
were more frequently supportive of THR
than not (Table 1). Editorials and systematic
reviews were the most evenly divided cate-
gories, with roughly equal frequency of
pro-THR and anti-THR ratings. Cross-
sectional studies, literature reviews, and quali-
tative studies were more frequently anti-THR.
Key Question 2
What proportion of THR articles are
funded by the tobacco, pharmaceutical, and
e-cigarette industries? About 23.9% (n = 197)
of articles were funded by the tobacco,
pharmaceutical, and e-cigarette industries or
some combination thereof. Overall, 14% of
articles were funded by the pharmaceutical
industry, 7% by the tobacco industry, and 7%
by the e-cigarette industry.
Key Question 3
Does the THR stance of industry-funded
THR research differ from non–industry-
funded research? Articles reporting any in-
dustry funding were signiﬁcantly more likely
to take a pro-THR position. In exact logistic
regression models taking into account sparse
data, the odds of taking a pro-THRstancewas
signiﬁcantly higher for articles funded or
supported by the e-cigarette industry (odds
ratio [OR]= 20.9; 95% conﬁdence interval
[CI] = 5.3, 180.7), the tobacco industry
(OR=59.4; 95% CI= 10.1, +inﬁnity), and
the pharmaceutical industry (OR=2.18;
95% CI= 1.3, 3.7). Ninety-ﬁve percent
of the e-cigarette industry–funded articles
took a pro-THR stance as did 88% of the
tobacco industry articles and 72% of the
pharmaceutical industry–funded articles. In
contrast, only 41.1% of articles without
any industry funding or afﬁliation took a
pro-THR stance (Figure 3).
Among empirical studies, tobacco industry
funding perfectly predicted a pro-THR
stance, so it was not included in the model.
E-cigarette industry funding was signiﬁ-
cantly associated with a pro-THR stance
(OR=16.4; 95% CI= 2.4, 701.8), as was
pharmaceutical funding (OR=2.1; 95%
CI= 1.03, 4.5) for empirical articles. Among
nonempirical studies, tobacco industry
funding was signiﬁcantly associated with
pro-THR stance (OR=19.1; 95% CI= 3.0,
799.5), as was e-cigarette industry funding
(OR=20.1; 95% CI= 3.2, 860.2) and
pharmaceutical industry funding (OR=2.4;
95% CI= 1.1, 5.3; Table 2).
DISCUSSION
This systematic review of industry funding
in the published literature on THR found
that 23.9% of included articles were funded
by industries with a ﬁnancial interest in
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promoting nicotine-containing products as
THR. Industry-funded articles were signiﬁ-
cantly more likely to support THR. Absent
these articles, the published literature did not
endorse THR,with 41.1% supporting, 10.4%
neutral, and 48.6% against THR. In com-
parison, 80.9% of industry-funded articles
endorsed THR. The impact of industry-
funded publications may have skewed
the overall debate in favor of product
substitution.
These ﬁndings are consistent with the
scientiﬁc literature showing that tobacco in-
dustry–funded research favors conclusions
supportive to the tobacco industry.28–32 This
includes industry research supporting nico-
tine’s beneﬁts for Alzheimer’s disease,33
neuroenhancement,34 and ulcerative co-
litis.35 Other studies also documented the
inﬂuence of pharmaceutical industry funding
onmultiple types of bias in scientiﬁc studies.36
This study suggests that major debates in
public health such as THRmay be shaped by
industry-interested nonempirical articles,
letters, and commentaries in the scholarly
literature.
The pharmaceutical industry was the most
common industry funder of THR articles.
This may be because pharmaceutical com-
panies have themost active interest in this area
or because there is less stigma associated
with disclosure of pharmaceutical funding
compared with disclosure of tobacco or
e-cigarette funding sources. The tobacco
industry’s history of funding scientiﬁc re-
search to undermine the evidence of harms
from tobacco is well documented.37–40 The
higher frequency of disclosed pharmaceutical
funding may be the result of undisclosed
tobacco and e-cigarette industry funding.
Future studies should address undisclosed
funding sources, which may be uncovered
from internal industry documents41,42 or by
tracing disclosed funding from authors’ past
publications.43,44
In addition, most published articles were
nonempirical research, editorials, letters, and
comments. Funding disclosure policies for
these types of publications may be more lax
than for empirical studies, so the presence of
industry funding reported in this study was
likely underestimated. Nonempirical studies
and reviews can have a substantial impact
on scientiﬁc debate, particularly when little
empiric evidence exists, as has been the case
with e-cigarettes. For example, one article,
which summarized the result of expert
opinion in a Delphi process,45 concluded that
e-cigarettes were 95% safer than cigarettes,
and it was widely cited8,46 as a deﬁnitive
scientiﬁc consensus, despite its tobacco and
e-cigarette funding source47 and lack of any
speciﬁc empirical evidence supporting the
TABLE 1—Stance on Tobacco Harm Reduction (THR) of Articles by the Primary Tobacco
Product Type, Year of Publication, First Author’s Country, Publication Type, and Funding
Source: January 1, 1992, to July 26, 2016
Total (n = 826),
No. (%)
Pro-THR (n = 406),
No. (%)
Neutral/Mixed
(n = 77), No. (%)
Anti-THR (n = 343),
No. (%)
Primary product type
E-cigarettes 404 (48.9) 199 (49.3) 38 (9.4) 167 (41.3)
Smokeless tobacco 161 (19.5) 75 (46.6) 12 (7.5) 74 (45.3)
Snus 142 (17.2) 59 (41.1) 17 (12.0) 66 (46.5)
Potentially reduced
exposure products
91 (11.0) 58 (63.7) 5 (5.5) 28 (30.8)
Other 28 (3.4) 15 (53.6) 5 (17.9) 8 (28.6)
Year of publication
Before 2004 75 (9.1) 39 (52.0) 4 (5.3) 32 (42.7)
Between 2004 and 2010 205 (24.8) 267 (48.8) 49 (11.7) 230 (39.5)
After 2010 546 (66.1) 100 (48.9) 24 (9.0) 81 (42.1)
First author’s country
United States 402 (48.7) 141 (35.1) 43 (10.7) 218 (54.2)
United Kingdom 151 (18.3) 98 (64.9) 13 (8.6) 40 (26.5)
Australia 51 (6.2) 35 (68.6) 3 (5.9) 13 (25.5)
Sweden 40 (4.8) 24 (60.0) 4 (10.0) 12 (30.0)
Canada 40 (4.8) 27 (67.5) 2 (5.0) 11 (27.5)
Italy 25 (3.0) 22 (88.0) 1 (4.0) 2 (8.0)
France 14 (1.7) 6 (42.9) 1 (7.1) 7 (50.0)
New Zealand 17 (2.1) 12 (70.6) 3 (17.7) 2 (11.8)
Switzerland 13 (1.6) 8 (61.5) 3 (23.1) 2 (15.4)
Other 73 (8.3) 33 (45.2) 4 (5.5) 36 (49.3)
Publication type
Nonempirical studies 173 (20.9) 102 (59.0) 17 (9.8) 54 (31.2)
Letter or commentary 283 (34.3) 142 (50.2) 16 (5.7) 125 (44.2)
Editorial 44 (5.3) 18 (40.9) 8 (18.2) 18 (40.9)
Qualitative 31 (3.8) 8 (25.8) 6 (19.4) 17 (54.8)
Literature review 38 (4.6) 15 (39.5) 7 (18.4) 16 (42.1)
Systematic review or
meta-analysis
24 (2.9) 10 (41.7) 4 (16.7) 10 (41.7)
Case studies 5 (0.6) 3 (60.0) 0 (0.0) 2 (40.0)
Cross-sectional studies 125 (15.1) 51 (40.8) 13 (10.4) 61 (48.8)
Case–control studies 8 (1.0) 4 (50.0) 0 (0.0) 4 (50.0)
Cohort studies 28 (3.4) 15 (53.6) 1 (3.6) 12 (42.9)
Quasi-experimental studies 49 (5.9) 25 (51.0) 3 (6.1) 21 (42.9)
Randomized controlled
trials
18 (2.2) 13 (72.2) 2 (11.1) 3 (16.7)
Fundinga
E-cigarette industry 57 (29.7) 53 (93.0) 2 (3.5) 2 (3.51)
Pharmaceutical industry 124 (64.6) 88 (71.0) 8 (6.5) 28 (22.6)
Tobacco industry 59 (30.7) 54 (91.5) 4 (6.8) 1 (1.7)
aOf the articles, 4%were funded bymultiple industries.Thus, the total number adds up tomore than 192
and total percentage also exceeds 100%.
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estimate of relative safety.48 Medical prac-
titioners and researchers need to be aware
of the presence and inﬂuence of industry
funding in THR when reviewing this evi-
dence base.
Disclosure of industry funding is necessary
but not sufﬁcient to minimize the bias in-
troduced by commercial interests in science.43
Some scientiﬁc journals and conferences have
adopted policies rejecting articles or abstracts
submitted by industry-funded scien-
tists44,49,50 on the grounds that the industry’s
ﬁnancial interests bias their research. This
systematic review suggests thewisdomof such
a strategy to avoid further industry-induced
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FIGURE 3—Stance on Tobacco Harm Reduction (THR) by Industry Funding Source: January 1, 1992, to July 26, 2016
TABLE 2—Exact Logistic Models Fit With Industry Funding or Afﬁliation Source as Predictors for Pro–Tobacco Harm Reduction (Pro-THR)
Stance and Research Article Type: January 1, 1992, to July 26, 2016
OR (95% CI) Industry-Funded Pro-THR Articles, No.
Is presence of industry funding or afﬁliation associated with pro-THR stance? (n = 749)
a
E-cigarette industry 20.9 (5.3, 180.7) 53
Tobacco industry 59.4 (10.1, +Inﬁnity) 54
Pharmaceutical industry 2.18 (1.3, 3.7) 88
Is presence of industry funding or afﬁliation associated with type of research article (empirical)? (n = 826)
E-cigarette industry 0.7 (0.4, 1.3) 20
Tobacco industry 2.3 (1.3, 4.2) 35
Pharmaceutical industry 1.3 (0.9, 2.2) 56
Among nonempirical research articles, is industry funding associated with pro-THR stance? (n = 459)
b
E-cigarette industry 20.1 (3.2, 860.2) 34
Tobacco industry 19.1 (3.0, 799.5) 22
Pharmaceutical industry 2.4 (1.1, 5.3) 51
Among empirical research articles, is industry funding associated with pro-THR stance? (n = 258)
E-cigarette industry 16.4 (2.46, 701.76) 19
Tobacco industryc . . . 32
Pharmaceutical industry 2.1 (1.03, 4.45) 37
Note. CI = conﬁdence interval; OR =odds ratio; THR= tobacco harm reduction.
aThe articles with THR stance coded as neutral or mixed (n = 77) were excluded from this analysis. Models take sparse data into account.
bHere, 77 articles taking a neutral THR stance were excluded.
cIn addition to excluding the 77 neutral THR articles, all 32 articles funded by or afﬁliated with the tobacco industry were dropped from the analysis as they
were all pro-THR (perfect prediction).
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bias that may perpetuate an industry-induced
health epidemic that continues to be the
leading preventable cause of death worldwide.
Limitations
This studywas limited to disclosed funding
sources—undisclosed fundingmay have had a
signiﬁcant effect on THRposition. The study
relied on a novel coding instrument to
measure position on THR, which was nev-
ertheless subjective. To address this inherent
limitation, we established detailed criteria to
enumerate the most common THR argu-
ments, investigators double-coded all articles
to minimize individual variance in assessment
of stance on THR, and an outside coder
validated a subset of articles. In addition,while
an independent research assistant blinded to
the article content extracted all funding dis-
closures, knowledge of authors’ conﬂicts of
interest might have biased the coders’ as-
sessment of stance. The inclusion of many
nonempirical articles and the heterogeneity in
the data set precluded the use of meta-analysis
or formal analysis of bias other than funding
bias. However, the data reﬂect most of the
published literature on THR as of 2016,
highlighting how nonempirical articles may
inﬂuence perceptions of scholarly consensus.
Despite these limitations, this study
demonstrates the importance of industry
conﬂict of interest in the THR debate. It also
points out several deﬁciencies in the current
body of literature on this topic, chief among
which is the lack of empirical studies com-
pared with opinion pieces, letters, and edi-
torials. Future studies may build on this work
by analyzing new research with clinical
outcomes conducted since 2016, evaluating
the risk of bias within different article types,
and assessing the role of undisclosed industry
funding on investigators’ conclusions.
Conclusions
Industry funding strongly inﬂuenced the
acceptance of THR as product substitution.
The THR scientiﬁc literature was dominated
by nonempirical articles, which were much
more likely to support THR if they received
industry funding. Industry funding of scien-
tiﬁc research has likely inﬂuenced perceptions
of consensus on THR as endorsing product
substitution as a viable health intervention,
when in fact the non–industry-funded
scientiﬁc literature remained divided on this
issue.
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